.png){kind=icon}
Return
PD-E2: a nano-scaled delivery for estradiol to decrease uterus damage and increase bone mineral density
.png){kind=icon}
PRE
AI
DOI：10.1039/d4tb02764g.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
It is well known that a specific application of 17 beta-estradiol (E2) is in hormone replacement therapy (HRT), but it is capable of inducing uterine gland cysts. However, the concentration of E2 that causes uterine gland cysts and bone loss remains unknown. To better understand this, we used an ovariectomized (OVX) mouse as the animal model and administered poly-alpha,beta-dl-aspartyl-Lys-coupled E2 (PD-E2) as the bone targeting agent. HPLC-FT-MS analysis showed that the amounts of E2 in the uterus and the femurs of the OVX mice treated with 2.3 mu mol kg-1 per day of E2 were 0.62 +/- 0.15 ng g-1 and 0.31 +/- 0.09 ng g-1, respectively, while the amounts of E2 in the uterus and the femurs of the OVX mice treated with 10 nmol kg-1 per day of PD-E2 were 0 +/- 0 ng g-1 and 1.11 +/- 0.27 ng g-1, respectively. The data suggested that if the amount of E2 in the uterus was equal to 0.62 +/- 0.15 ng g-1, the uterine gland will form cysts, and if the amount of E2 in the femurs was less than 0.31 +/- 0.09 ng g-1, the bone loss will be significant. Furthermore, the nano-scaled PD-E2 agent reported in this study provides an innovative strategy for HRT.
Keywords:
REPLACEMENT
HORMONE
THERAPY
SAFETY
Journal
IF:
5.7
Papers:
1.1W
Citations:
4.3W
Organization
No organization information available
Cited Papers
Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms.png)
MATURITAS
MATURITASIF3.6
PREAI
ShareSaveShareSaveMetabolic flexibility in postmenopausal women: Hormone replacement therapy is associated with higher mitochondrial content, respiratory capacity, and lower total fat massACTA PHYSIOLOGICA
OAAI
ACTA PHYSIOLOGICAIF5.6
OAAIShareSave
View more